Abbott Laboratories
Here’s whether Abbott Laboratories (ABT) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Neutral.
Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+4.64% over 10 days); 3-month momentum positive (+31.7%). Concerns: RSI 72 — overbought, elevated pullback risk; weak 1-year return of -13.9%; declining volume on rally — weak conviction (0.66x 30d avg). Currently 19.1% off its 52-week high. Score: +2/7.
ABT is in a confirmed uptrend, trading above both its 50-day ($97.63) and 200-day ($107.36) moving averages. With an RSI of 72.2, momentum has stretched into overbought territory — short-term pullbacks are common from these levels. The 1-year return of -13.9% compares to +20.4% for SPY (trailed the market by 34.3%).